GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artelo Biosciences Inc (NAS:ARTLW) » Definitions » Shiller PE Ratio

Artelo Biosciences (Artelo Biosciences) Shiller PE Ratio : (As of Jun. 06, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Artelo Biosciences Shiller PE Ratio?

Note: If the price history is too short, we do not calculate current Shiller PE for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Artelo Biosciences Shiller PE Ratio Historical Data

The historical data trend for Artelo Biosciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artelo Biosciences Shiller PE Ratio Chart

Artelo Biosciences Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Artelo Biosciences Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Artelo Biosciences's Shiller PE Ratio

For the Biotechnology subindustry, Artelo Biosciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Artelo Biosciences's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Artelo Biosciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Artelo Biosciences's Shiller PE Ratio falls into.



Artelo Biosciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Artelo Biosciences's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Artelo Biosciences's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0/131.7762*131.7762
=0.000

Current CPI (Mar. 2024) = 131.7762.

Artelo Biosciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201405 0.000 100.373 0.000
201408 0.000 100.352 0.000
201411 0.000 99.635 0.000
201502 0.000 99.032 0.000
201505 0.000 100.333 0.000
201508 0.000 100.548 0.000
201511 0.000 100.135 0.000
201602 0.000 100.040 0.000
201605 0.000 101.355 0.000
201608 0.000 101.617 0.000
201611 0.000 101.829 0.000
201702 0.000 102.779 0.000
201705 0.000 103.256 0.000
201708 0.000 103.587 0.000
201711 0.000 104.072 0.000
201802 0.000 105.052 0.000
201805 0.000 106.148 0.000
201808 0.000 106.383 0.000
201811 0.000 106.338 0.000
201902 0.000 106.649 0.000
201905 0.000 108.048 0.000
201908 0.000 108.245 0.000
201911 0.000 108.519 0.000
202002 0.000 109.139 0.000
202005 0.000 108.175 0.000
202008 0.000 109.662 0.000
202011 0.000 109.793 0.000
202102 0.000 110.968 0.000
202105 0.000 113.576 0.000
202108 0.000 115.421 0.000
202111 0.000 117.269 0.000
202203 0.000 121.301 0.000
202206 0.000 125.017 0.000
202209 0.000 125.227 0.000
202212 0.000 125.222 0.000
202303 0.000 127.348 0.000
202306 0.000 128.729 0.000
202309 0.000 129.860 0.000
202312 0.000 129.419 0.000
202403 0.000 131.776 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Artelo Biosciences  (NAS:ARTLW) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Artelo Biosciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Artelo Biosciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Artelo Biosciences (Artelo Biosciences) Business Description

Traded in Other Exchanges
Address
505 Lomas Santa Fe, Suite 160, Solana Beach, CA, USA, 92075
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing and commercializing treatments that control endocannabinoid system. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.

Artelo Biosciences (Artelo Biosciences) Headlines

From GuruFocus

Artelo Biosciences to Present at Sequire Biotechnology Conference on February 2nd

By Stock market mentor Stock market mentor 01-26-2023